Navigation Links
First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries

METEOR Trial Shows CRESTOR Slowed Progression Of Atherosclerosis In People At Low-Risk* Of Coronary Heart Disease

LONDON, March 26, 2006-AstraZeneca today announced that the METEOR clinical trial of CRESTOR is the first study to show a positive effect on atherosclerosis in people with early signs of carotid artery disease and at low risk of coronary heart disease (CHD).
The study, using CRESTORTM (rosuvastatin) 40mg and presented at 56th Scientific Sessions of the American College of Cardiology, resulted in subjects showing a significantly slower rate of progression of atherosclerosis when compared to placebo. When assessed vs. baseline, no significant progression was observed in the 40 mg rosuvastatin arm over the two-year duration of the study, while significant progression vs. baseline was observed in the placebo arm.

The data demonstrated that the CRESTOR 40mg patients, with moderately increased LDL (‘bad’) cholesterol levels (mean 154 mg/dL) and no established atherosclerosis, experienced a 0.0014 mm/yr decrease in the mean maximum carotid intima-media thickness – a marker of atherosclerotic burden,compared to a progression of 0.0131 mm/yr for those on placebo (p<0.0001). CRESTOR 40 mg was well tolerated during the two years of the study.

With completion of this study, CRESTOR has now been studied across the atherosclerosis disease spectrum, first with ASTEROID, which included patients with established coronary artery disease and at a high risk of CHD events, and now with METEOR, which evaluated CRESTOR in asymptomatic subjects with early disease and at low CHD risk.

“It’s exciting to see that by using rosuvastatin we can potentially slow or even stop the disease progression in people with relatively modest atherosclerosis,” said lead investigator John R. Crouse, III, M.D., Professor of Medicine and Public Health Sciences and Associate Director of the Wake Forest University School of Medicine (WFUSM) General Clinical Research Centre. “METEOR provides evidence that the effect of rosuvastatin on dyslipidaemia translates into a beneficial effect on the progression of atherosclerosis.”

Atherosclerosis occurs when there is a build-up of fatty or fibrous deposits, to form areas called plaques, in the artery wall. The build-up of plaques causes the artery to narrow and this can reduce the blood supply to vital organs such as the heart and brain, resulting in symptoms such as angina or transient ischaemic attacks. Plaques can also rupture leading to thrombus formation, which can result in a sudden, complete blockage of blood flow. In the heart, this causes a heart attack, and in the brain, this causes a stroke. Atherosclerosis is a progressive disease and the main cause of cardiovascular disease – the number one killer worldwide.

A recently published independent post hoc analysis combining data from four prospective trials, including ASTEROID, showed that by substantially both decreasing LDL-C and increasing HDL-C by more than 7.5 percent, a beneficial effect on atherosclerosis can be achieved. In METEOR, CRESTOR was associated with a 48.8 percent reduction in LDL-C and an 8.0 percent increase in HDL-C (both p<0.0001 vs placebo). These results are consistent with the above finding and provide additional confirmation that the lowering of LDL-C and raising of HDL-C offered by CRESTOR translate into beneficial effects on atherosclerosis.

METEOR (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin) was a 24-month, randomised, double-blind, placebo-controlled, international study to evaluate the effect of CRESTOR 40mg in 984 asymptomatic, hypercholesterolaemic patients with a low risk of coronary heart disease (Framingham ten year risk <10 percent ) and evidence of sub-clinical atherosclerotic disease as determined by a thickened carotid artery wall (maximum intima media thickness (IMT) >1.2 and <3.5 mm). METEOR used B-mode ultrasound imaging to assess and measure change in mean maximum IMT of 12 vessel sites in the carotid artery. The study evaluated low risk subjects not indicated for statin therapy to permit inclusion of a comparative placebo arm.

Currently, CRESTOR is indicated for the treatment of lipid disorders. The results from the METEOR study, supported by data from the ASTEROID study and including the ORION trial, formed the basis of the atherosclerosis regulatory submissions filed in the European Union and the United States in January 2007. These submissions seek to expand the use of CRESTOR to include the treatment of atherosclerosis with the purpose of impacting the progression of the disease in patients in whom lipid-lowering therapy is indicated.

These new results from METEOR add to the wealth of CRESTOR efficacy data from its extensive GALAXY clinical trials programme, designed to address important unanswered questions in statin research and to investigate the impact of CRESTOR on cardiovascular risk reduction and patient outcomes. Currently, more than 63,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Programme.

CRESTOR has now received regulatory approvals in over 90 countries across five continents. Over 9 million patients have been prescribed CRESTOR worldwide. Data from clinical trials and marketed use shows that the safety profile for CRESTOR is in line with other marketed statins. Annual sales for Crestor exceeded $2 billion for the first time in 2006.

The 40 mg dose is the highest registered dose of CRESTOR. CRESTOR should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries, the usual recommended starting dose of CRESTOR is 10mg. The 40mg dose should only be used in patients who have not ac hieved their LDL-C goal utilizing the 20mg dose of CRESTOR.

25 March 2007

Media enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033

Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Jörgen Winroth, Tel: +1 (212) 579 0506
Ed Seage, Tel: +1 302 886 4065

Notes To Editors
* People at low-risk of coronary heart disease as described in the METEOR study had a Framingham 10- year risk of less than 10 percent. The Framingham risk score is a method to determine an individual's risk of having either a fatal or non-fatal heart attack over the following 10 years. The risk score is based on an
individual's cholesterol level, blood pressure, smoking status, age and gender.

ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden) was a 104-week, open label, single-arm, blinded endpoint study designed to study the effect of CRESTOR 40mg in 507 patients who had undergone coronary angiography and who had evidence of coronary artery disease (CAD).
Key findings from ASTEROID include:

CRESTOR brought about a 0.79 per cent (median) reduction in percent atheroma volume in the entire target vessel (p<0.001) – first primary endpoint
CRESTOR brought about a 9.1 per cent (median) reduction in total atheroma volume in the most diseased 10mm segment of the target vessel (p<0.001) – second primary endpoint
CRESTOR brought about a 6.8 per cent (median) reduction in total atheroma volume in the entire target vessel (p<0.001) – secondary endpoint
These changes were associated with a 53 per cent reduction in LDL-C (p<0.001) and a 15% increase in HDL-C (p<0.001)
ORION (Outcome of Rosuvastatin Treatment on Carotid Artery Atheroma: a Magnetic Resonance Imaging ObservatioN) was the first study to use advanced, high resolution MRI to investigate the effect of a statin – CRESTOR - on the change in the composition of plaques in the carotid artery wall. Forty-three (43) patients with moderate hypercholesterolemia and established carotid atherosclerosis were treated with either CRESTOR low dose (5 mg) or high dose (40/80 mg) for two years.


Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc (NASDAQ: ... agreements to resolve virtually all known U.S. mesh product ... to resolve the known remaining U.S. claims at reasonable ... beginning in the fourth quarter of 2017 and continuing ... its second quarter 2017 results, the Company intends to ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage has been ... Risk Management Solution Innovations and Security Solution for Government Innovations. Both gold awards ... and its DHS SAFETY Act-designated enterprise security assessment approach. , The ninth annual ...
(Date:8/23/2017)... ... August 23, 2017 , ... The non-profit ... holding an inaugural State of the Science Symposium in partnership with the Global ... 2017. , This symposium provides a forum for global leaders in human nutrition ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a ... Migraine Relief with the 2017 Women’s Choice Award. The identification by women of an ... out of 4 migraine sufferers are women. In a survey taken by the Women’s ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western ... spoke at a popular international aesthetics conference for medical professionals about the positive ... patients’ health and his growing practice. , Dr. George K. Ibrahim ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent ... these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year ... came in. Now, it's time to announce the winners of the sixth annual Photo Contest, ...
Breaking Medicine News(10 mins):